MedPath
HSA Approval

EVIPSYZED 25 QUETIAPINE FUMARATE TABLETS USP 25MG

SIN17066P

EVIPSYZED 25 QUETIAPINE FUMARATE TABLETS USP 25MG

EVIPSYZED 25 QUETIAPINE FUMARATE TABLETS USP 25MG

August 23, 2024

ZYFAS PHARMA PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantZYFAS PHARMA PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

N05AH04

Manufacturer Information

ZYFAS PHARMA PTE. LTD.

DR. REDDY'S LABORATORIES LTD

Active Ingredients

QUETIAPINE FUMARATE EQV. QUETIAPINE

25 mg

Quetiapine

Documents

Package Inserts

Evipsyzed 25 Tablet PI.pdf

Approved: August 23, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.